Systimmune reported that izalontamab brengitecan (iza‑bren), developed under license by Bristol Myers Squibb in China, met both progression‑free survival and overall survival endpoints in a phase‑3 trial for advanced triple‑negative breast cancer. The readout marks a major registration milestone for the licensee and could trigger regulatory filings and commercialization planning in China. Systimmune framed the positive outcome as validation for its next‑generation payload and antibody‑drug conjugate design. BMS, as the licensee, stands to benefit commercially if the local approval path proceeds on schedule. The success may catalyze further partnering and regional licensing strategies for ADCs in high‑unmet lung and breast cancers, and will be followed for safety details and subgroup analyses.